Biofrontera Aktie - BFRI

Biofrontera Inc (BFRI) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Premium

Current Price

0,9677

( -2,74% )

Gebot

0,72

Fragen

1,16

Volumen

205.521

0,915 Tagesbereich 1,00

0,5547 52-Wochen-Bereich 1,19

Marktkapitalisierung

11,62M

Handelsende

0,995

Handelsbeginn

0,99

Letzte Trade

0.9889

Letzter Handelszeitpunkt

Finanzvolumen

US$ 197.453

VWAP

0,960743

Durchschnittliches Volumen (3 Mio.)

US$ 172.904

Ausgegebene Aktien

12.007.558

Dividendenrendite (LTM)

Kurs-Gewinn-Verhältnis

-0,84

Gewinn pro Aktie (EPS)

-1,02

Erlöse (LTM)

43,2M

Nettogewinn (LTM)

-11,09M

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic kera... Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. Mehr anzeigen

Sektor

Healthcare

Branche

Pharmaceuticals

Website

www.biofrontera-us.com

Hauptsitz

Woburn, United States

Gegründet

2026

Biofrontera Inc is listed in the Healthcare sector of the NASDAQ with ticker BFRI. The last closing price for Biofrontera was US$1,00. Over the last year, Biofrontera shares have traded in a share price range of US$ 0,5547 to US$ 1,19.

Biofrontera currently has 12.007.558 shares in issue. The market capitalisation of Biofrontera is US$11,62 million. Biofrontera has a price to earnings ratio (PE ratio) of -0.84.

Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the...

Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update

Woburn, MA, May 14, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) (the "Company"), a...

Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis

The second annual #HatsonforAK Campaign runs May 18–24, 2026, culminating on Global Actinic Keratosis (AK...

Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026

WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the...

Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE...

Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the...

Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris

• Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz® PDT versus vehicle...

U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable

WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company...

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities

Phase 1 maximal-use pharmacokinetics (PK) study completed in support of planned U.S. label expansionData to...

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma

Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026If approved, Ameluz® would...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0.0897	10.2164009112	0.878	1.0499	0.84505	172538	0.98628615	CS
4	-0.1823	-15.852173913	1.15	1.19	0.7304	225375	0.93522144	CS
12	0.1092	12.7198602213	0.8585	1.19	0.7304	163115	0.96950969	CS
26	0.1377	16.5903614458	0.83	1.19	0.5547	307688	0.84153257	CS
52	0.3468	55.8544048961	0.6209	1.19	0.5547	244004	0.86134738	CS
156	0.4787	97.8936605317	0.489	12.9857	0.415	477873	1.13865167	CS
260	-3.1223	-76.3398533007	4.09	14.63	0.38	1471390	5.26154697	CS

BFRI - Frequently Asked Questions (FAQ)

What is the current Biofrontera Inc share price?

The current share price of Biofrontera Inc is US$ 0,9677

How many Biofrontera Inc shares are in issue?

Biofrontera Inc has 12.007.558 shares in issue

What is the market cap of Biofrontera Inc?

The market capitalisation of Biofrontera Inc is USD 11,62M

What is the 1 year trading range for Biofrontera Inc share price?

Biofrontera Inc has traded in the range of US$ 0,5547 to US$ 1,19 during the past year

What is the PE ratio of Biofrontera Inc?

The price to earnings ratio of Biofrontera Inc is -0,84

What is the cash to sales ratio of Biofrontera Inc?

The cash to sales ratio of Biofrontera Inc is 0,24

What is the registered address of Biofrontera Inc?

The registered address for Biofrontera Inc is 660 Main Street, Woburn, Massachusetts, 01801

What is the Biofrontera Inc website address?

The website address for Biofrontera Inc is www.biofrontera-us.com

Which industry sector does Biofrontera Inc operate in?

Biofrontera Inc operates in the Pharmaceuticals sector

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Biofrontera Inc (BFRI)

Biofrontera Inc (BFRI) Aktie

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Über Biofrontera Inc

BFRI Neueste Nachrichten

Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update

Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis

Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026

Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris

U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma

Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update

Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis

Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026

Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026

Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris

U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 To Be Unpatentable

Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma

Biofrontera Reports Positive Phase 3 Data for Ameluz in Actinic Keratosis

Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint

BFRI - Frequently Asked Questions (FAQ)

BFRI Trades

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich GRATIS und erhalten Sie:

Werbung entfernen